HOME >> BIOLOGY >> NEWS
Children's Hospital Boston receives more than $10 million to help make smallpox vaccine safer

Children's Hospital Boston (CHB) has secured contracts totaling nearly $10.5 million through the National Institutes of Health to study a potentially life-threatening complication of smallpox immunization known as eczema vaccinatum (EV). The goal is to reduce the risk of EV and develop a safer smallpox vaccine.

EV is a severe skin infection caused by vaccinia, the live virus used in the smallpox vaccine. The risk of EV has been a major barrier to reintroducing widespread smallpox immunization. Routine vaccination ended in the U.S. in 1972, so many Americans lack immunity to smallpox, which is now seen as a potential weapon of bioterrorism.

Most susceptible to EV are the millions of Americans, including many young children, who have a history of atopic dermatitis, the allergy-related skin condition better known as eczema. People with weakened immune systems also are at risk. If not treated in time, EV has a mortality rate of up to 6 percent, and as high as 30 percent among children under age 2.

CHB's Division of Immunology will play a leading role in a nationwide research network, launched by the National Institute of Allergy and Infectious Diseases (NIAID), that will investigate why atopic dermatitis predisposes smallpox vaccine recipients to EV.

"Since 5 percent of kids and about 1 percent of adults have atopic dermatitis, the risk is great should a decision be made to mass vaccinate," says Dr. Raif Geha, chief of Immunology at CHB. "EV can develop even in people with mild atopic dermatitis, as well as healthy people who had atopic dermatitis in the past. Also, since the virus in the smallpox vaccine is live, it can spread from contact with people who have been vaccinated."

Geha will head up the Animal Studies Consortium under the contract, coordinating animal studies at CHB and five subcontracting institutions under a five-year, $10 million grant. Geha's own lab will establish a mouse model for atopic dermatitis, explo
'"/>

Contact: Mary-Ellen Shay
mary.shay@childrens.harvard.edu
617-355-6420
Children's Hospital Boston
23-Jul-2004


Page: 1 2

Related biology news :

1. Childrens eating patterns show striking changes in two decades
2. Childrens Memorial, TGen announce partnership
3. Federal grant supports advances in infant heart disease at Childrens Hospital of Philadelphia
4. Packard Childrens Hospital gift creates new biotech research center for childrens health
5. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician
6. Childrens Hospital Boston researchers regenerate zebrafish heart muscle
7. Childrens Hospital Boston researchers use therapeutic cloning to create functional tissue in cows
8. Childrens book explores why animals stay home to help
9. Hopkins Childrens Center researchers find cause for common kind of dwarfism
10. Transplanted human stem cells develop into broad range of tissues, persist over a year in research at The Childrens Hospital of Philadelphia
11. Immunologist at the Childrens Hospital of Philadelphia receives national award in clinical laboratory immunology

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/5/2020)... , ... March 05, 2020 , ... ... a strategic partnership agreement with Phoenestra GmbH to accelerate Cytonus’ existing products and ... in San Diego, California. Phoenestra is a biotech company located in Austria. ...
(Date:3/5/2020)... , ... March 05, 2020 , ... Patients in need ... dental implants from Dr. Nickelice Brand of Dental Implants of Ocala. Same-day dental ... get an entirely new smile in just one day. This treatment utilizes advanced technology ...
(Date:3/5/2020)... BOSTON (PRWEB) , ... March 05, 2020 , ... ... its AlphaSTEM Test™ technology . The AlphaSTEM Test™ is the first, ... tissue stem cells. Other technologies that attempt to provide information about the ...
Breaking Biology News(10 mins):
(Date:4/1/2020)... CITY, and LA JOLLA, Calif. (PRWEB) , ... March 31, 2020 ... ... tools, and La Jolla Institute for Immunology (LJI), announced today that they will use ... allowing CoVIC to move therapeutic candidates to the clinic as early as this summer. ...
(Date:3/27/2020)... ... March 25, 2020 , ... ... opening of its veterinary histopathology laboratory located centrally in the midwest for ... ability to work with a highly motivated, independent, professional team that is ...
(Date:3/19/2020)... ... March 17, 2020 , ... ... pioneering gene circuit company Senti Biosciences, Inc. (Senti) to accelerate the clinical ... tumor indications. The collaboration will leverage RoosterBio’s human mesenchymal stem/stromal cell (hMSC) ...
(Date:3/13/2020)... ... March 12, 2020 , ... ... Microbiome Ireland SFI Research Center (APC), a pioneer in the field of microbiome ... play a significant role in human health, based at University College Cork and ...
Breaking Biology Technology:
Cached News: